CMO acquires 1.5-acre lot for new facility expected to launch in 2020

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)
Grand River Aseptic Manufacturing has purchased a new lot of land to expand its manufacturing capabilities as growth in the market drives demand, says CEO.

The parenteral contract manufacturing organization (CMO) has signed purchase agreements to acquire a 1.5-acre lot on Butterworth Street in Grand Rapids, Michigan.

The new site is less than a quarter mile away from GRAM's existing manufacturing facility near downtown Grand Rapids and less than a mile away from its finishing facility on Godfrey Street.

“The land purchase will support GRAM’s new, high-speed commercial scale equipment,”​ said Nick Bykerk, the company’s director of business development and finance.

GRAM’s continued growth with its current customers and their commercial needs as well as overall growth in the market has driven demand for the expansion, Tom Ross, GRAM president and CEO told us.

The new site will increase GRAM’s existing 40,000-square-foot cGMP space and will eventually house cleanroom space, including new isolator technology and fully integrated manufacturing and packaging lines.

The next steps involve groundbreaking, qualifying the new equipment, and launch in 2020, Ross explained. The deal is expected to close within 90 days.

GRAM, formed in 2010, also expanded its fill/finish footprint in 2014 with the addition of a 28,000-square-foot facility. It has grown from 16 employees to more than 160 over the past seven years.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars